A comprehensive view of AstraZeneca AB. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca partners with US Grail to develop diagnostic assays to use with AstraZeneca’s cancer therapies using Grail’s technology to detect cancer signals in blood; initial focus on high-risk, early-stage cancer with more assays in coming years
Published: June 09, 2022 by SeeNews Pharmaceuticals
HHS reports sales of Pfizer’s COVID-19 oral antiviral Paxlovid outpaced drugs from other firms; 162,000 Paxlovid courses used in US in past week compared to 20,000 courses of Merck and Ridgeback’s Lagevrio, 16,000 courses of AstraZeneca’s Evusheld
Published: May 27, 2022 by FiercePharma
AstraZeneca gets license to develop, sell RQ Biotechnologies' pre-clinical COVID antibody therapies in US$157M deal; deal includes therapies for patients with compromised immune systems as AstraZeneca moves to build immune-focused therapy portfolio
Published: May 19, 2022 by The Peninsula
AstraZeneca and Avillion’s PT027 albuterol, budesonide rescue inhaler shows significant reduction in risk of severe exacerbation in patients with moderate to severe asthma in Phase 3 trial; asthma affects 25 million in US, 339 worldwide
Published: May 17, 2022 by Business Wire
Biotech Pulse: FDA approves earlier use of Enhertu from AstraZeneca, Daiichi for adults with metastatic breast cancer; AstraZeneca reports Farxiga hits goal in heart failure patients, and Ultomiris significantly reduces relapse of autoimmune disease
Published: May 11, 2022 by Benzinga

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count